Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea; BK Plus Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea; SML biopharm, Gyeonggi-do, Bucheon, Republic of Korea.
Department of Medical and Biological Sciences, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea; BK Plus Department of Biotechnology, The Catholic University of Korea, Gyeonggi-do, Bucheon, Republic of Korea.
Vaccine. 2023 Mar 10;41(11):1892-1901. doi: 10.1016/j.vaccine.2023.02.005. Epub 2023 Feb 7.
Owing to the rapid spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its variants, the development of effective and safe vaccines has become a priority. The measles virus (MeV) vaccine is an attractive vaccine platform as it has been administered to children for more than 40 years in over 100 countries. In this study, we developed a recombinant MeV expressing the full-length SARS-CoV-2 spike protein (rMeV-S) and tested its efficacy using mouse and hamster models. In hCD46Tg mice, two-dose rMeV-S vaccination induced higher Th1 secretion and humoral responses than one-dose vaccination. Interestingly, neutralizing antibodies induced by one-dose and two-dose rMeV-S immunization effectively blocked the entry of the α, β, γ, and δ variants of SARS-CoV-2. Furthermore, two-dose rMeV-S immunization provided complete protection against SARS-CoV-2 in the hamster model. These results suggest the potential of rMeV-S as a vaccine candidate for targeting SARS-CoV-2 and its variants.
由于严重急性呼吸综合征冠状病毒 2（SARS-CoV-2）及其变体的迅速传播，开发有效和安全的疫苗已成为当务之急。麻疹病毒（MeV）疫苗是一种有吸引力的疫苗平台，因为它已经在 100 多个国家中为儿童接种了 40 多年。在这项研究中，我们开发了一种表达全长 SARS-CoV-2 刺突蛋白的重组 MeV（rMeV-S），并使用小鼠和仓鼠模型测试了其功效。在 hCD46Tg 小鼠中，两剂量 rMeV-S 疫苗接种诱导的 Th1 分泌和体液反应高于一剂接种。有趣的是，一剂和两剂量 rMeV-S 免疫诱导的中和抗体可有效阻止 SARS-CoV-2 的 α、β、γ 和 δ 变体进入。此外，两剂量 rMeV-S 免疫接种可在仓鼠模型中完全保护免受 SARS-CoV-2 的侵害。这些结果表明 rMeV-S 作为针对 SARS-CoV-2 及其变体的疫苗候选物具有潜力。
Zotero 插件
